Pharmaceuticals, Biotechnology and Life Sciences
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a …
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Co…
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Co…
Conference call and webcast to be held at 10:00 a.m. ETBOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that …
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18…
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU…
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU…
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU…
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU…
– Company receives FDA Priority Review with PDUFA date set for July 20, 2021 – – Submission data for PFIC…